AstraZeneca China Ecosystem Conference 2024: Driving Global Health Innovation Through Collaboration

Building a Diverse and International Healthy Innovation Ecosystem

AstraZeneca has been deeply rooted in China for over 30 years, coexisting and thriving with the industry, and resonating with China's development. Since its inception in 2018, AstraZeneca China's Ecosystem Conference has, over the course of six years, gathered a large number of industry experts and cross-sector partners.Clinical Discipline Development, Upstream and Downstream Enterprise Ecosystem Cooperation, Capital Empowerment of Science and Technology Innovation Incubation, Government-Enterprise Cooperation Modelin various aspects, continuously driving innovation, building a diversified and innovative health ecosystem, and jointly promoting the long-term high-quality development of the healthcare industry.

Standing at a new starting point, "expanding" the domestic and international health innovation ecosystem, deepening two-way exchanges between China and the world, promoting local innovation in China to reach the global stage, and benefiting patients in China and around the world have become key strategic goals for AstraZeneca in its next phase of development.

This year, the 7th AstraZeneca China Ecosystem Conference will be structured as "1+11+1+1," namely, 1 main summit + 11 themed sub-forums + 1 ecosystem banquet + 1 interactive booth. Experts from various circles will focus on the latest...Policy Trends, International Exchange and Cooperation, Innovation Empowering Clinical Practice, Integration of Chinese and Western Medicine Innovation, Capital Enabling Globalization, Digital Chronic Disease Management, Rare Disease Innovative Diagnosis and Treatment, Precision Oncology Diagnosis, Patient EmpowermentFrontier topics, conducting multiple high-quality dialogues with foresight, predictability, and authority.

This conference has achieved even moreGlobal Collaboration, AstraZeneca will not only share the latest progress and achievements in international expansion with the industry, but also invited guests fromUnited Kingdom, Sweden, Australia, South Korea, Saudi Arabia, Mexico, Thailand, Hong Kong, ChinaDistinguished guests from home and abroad will participate in multiple specialized international exchange sub-forums and events, fully creating an international cooperation and exchange platform. This will further implement, deepen, and extend the "going global" strategy, promoting Chinese innovative enterprises, innovative models, and innovative achievements to reach the world and benefit more patients. Partners from all sectors are welcome to join the group chat!

Empowering Chinese Innovation to Reach the World

This conference also attracted nearly a thousand top experts, prominent guests, high-growth companies, technical experts, and professional investors in the field of life and health from home and abroad.

May 11, AstraZeneca has carefully arranged multiple sub-forums related to vertical fields, focusing onDigital Chronic Disease Management, Precision Oncology Diagnosis, Innovative Rare Disease Diagnosis and Treatment, Innovative Pediatric Respiratory Diagnosis and Treatment, Patient Organization Engagement, Multi-layered Healthcare Security, Overseas Cooperationand other industries focus on key issues for discussion.

In the field of three-high chronic disease management, AstraZeneca supports the establishmentMMC (Standardized Metabolic Diseases Management Center)To support the integrated diagnosis and treatment of metabolic diseases throughout the entire patient journey. With the implementation of MMC across China's 31 provinces, municipalities, and autonomous regions, AstraZeneca has begun expanding it to grassroots levels by launching the "1+X" model, aiming to extend MMC to every county, town, and township, reaching more community health centers. At this sub-forum,Some hospitals of MMC, as implementers and technical supporters, will also share the successful implementation experience of the "1+X" model in different regions from practical and technical perspectives.

At the same time, AstraZeneca has also drawn on the construction and practical achievements of MMC to establishCough and Wheeze Management Center (CWMC), Promoting the Integrated Whole-process Management for Patients with Respiratory Diseases.The connotation and value of CWMC will be deeply interpreted at the forum.In addition, the integration of chronic disease management in and out of hospitals, as well as online and offline approaches, is also an important topic of this forum. We look forward to your participation to jointly promote the digitalization of chronic disease management!

Precision Diagnosis of TumorsIt has always been a key focus area for AstraZeneca. In response to the uneven distribution of oncology medical resources, some medical pioneers have realized that establishing regional diagnostic centers can improve the accessibility of precise cancer diagnosis. At this forum, hospital experts from different regions across China will discussConstruction and Implementation Challenges of Regional Diagnostic Centers: How Hospitals, Clinics, Pathology Departments, and Other Stakeholders Can Collaborate Effectivelyand other topics were discussed.

In response to the growing demand for early screening, early diagnosis, and early treatment of cancer, AstraZeneca will also collaborate with medical and research partners to explore new developments in molecular pathology testing for breast cancer, new opportunities for digital pathology and artificial intelligence in the era of precision oncology, as well as the application and research of new technologies for early liver cancer screening.

AstraZeneca, with a patient-centric approach, is continuously improving the accessibility of rare disease drugs. AstraZeneca Global is integrating R&D resources to advance over 20 clinical development programs targeting various indications, building on its portfolio of 11 molecular products for rare diseases. To bring together authoritative experts and cutting-edge innovative resources in the rare disease field, and to foster forward-looking, authoritative, and predictive exchanges within the rare disease industry, AstraZeneca aims to ensure that rare diseases are no longer rarely treated. The company is strengthening academic and policy exchanges in China’s rare disease sector while promoting the development of innovative technologies for rare disease diagnosis and treatment.

Innovative Diagnosis and Treatment of Rare DiseasesThe sub-forum will collaborate with policy experts, medical experts, and cutting-edge outstanding enterprises to focus onRare Disease Policies, Latest Advances in Diagnosis and Treatment, Innovation Development Prospects, Patient Accessibility and AssuranceIn-depth exchanges will be conducted in multiple directions, jointly exploring innovative technologies and solutions for each link in the screening, diagnosis, treatment, and management of rare diseases. Efforts will focus on actively seeking pathways to address deep-rooted pain points that have long existed in these areas. The goal is to gradually achieve the target of "early detection, early diagnosis, and early treatment" in the field of rare diseases, and jointly promote the high-quality development of the prevention and treatment of rare diseases.

AstraZeneca is committed to improving the scientific diagnosis and treatment standards as well as comprehensive disease management for children with cough, asthma, and respiratory immune diseases. It actively supports projects such as the "Ten Thousand Nebulization Rooms" and "Standardized Pediatric Asthma Clinics," and has established close cooperative relationships with thousands of medical institutions across China, fully ensuring the safety and health of children.

This conference will focus onCurrent Status and Innovative Management Models for Diagnosis and Treatment of Respiratory Diseases in Children Inside and Outside the Hospital, inviting industry experts, medical and pharmaceutical experts, and innovative partner enterprises to give keynote speeches and solution roadshows. Through ecological co-construction, the nebulization model in hospital emergency departments will be reformed, promoting the iteration of service models extending from inside hospitals to outside, with greater emphasis on long-term management of home nebulization for children and asthma.

AstraZeneca Collaborates with Oncology, Rare Disease, and Chronic Illness Patient Organizations for the First Time, Inviting Policy Researchers, Experts in Disease Treatment, and Guests from Internet Healthcare and Retail Sectors to Engage in Interactive, Forward-Looking Discussions on Policy Advocacy, Patient Disease Management Capabilities, and the Sustainable Development of Patient Organizations in China, Based on Patient Needs and Voices, Aiming to...Helping Chinese patients improve their quality of life and empowering patient organizations for long-term development, contributing to the high-quality development of China's pharmaceutical industry.

At this forum, AstraZeneca will collaborate with multiple parties to explore the expansion and quality improvement of inclusive health insurance under multi-level protection, as well as the innovative integration of pharmaceutical and insurance solutions, jointly promoting enhancements.Patient Access。

At this year's conference, AstraZeneca is hosting five special sub-forums on overseas cooperation, includingSaudi Arabia, Mexico, Thailand, Australia, Hong Kong, China, making great efforts to build an international cooperation and exchange platform, further implementing, deepening, and extending the "going out" strategy, promoting Chinese innovative enterprises, innovative models, and innovative achievements to reach the world and benefit more patients. Partners from all walks of life are welcome to join the group chat!

In addition, AstraZeneca has specially set up an off-site interactive area to showcase excellent innovative cooperation cases and achievements while establishing government investment attraction zones and cooperation negotiation areas to communicate closely with potential partners and improve resource connection efficiency. Moreover, AstraZeneca has specially designed multiple visits to the China Health IoT Innovation Center and Wuxi International Life Science Innovation Park, inviting ecosystem partners from all sectors to visit AstraZeneca's ecosystem innovation achievements on-site.

Unitedly Promoting the Continuous Expansion of the Health Innovation Ecosystem, Collaboratively Empowering New Quality Productivity to Integrate Globally. Welcome Soon.Scan the QR code to follow the [International Life Science Innovation Park] WeChat Official Account and register for the conference.Participate in the 7th AstraZeneca China Ecosystem Conference. From May 10th to 11th, we look forward to meeting you by the Taihu Lake to jointly plan the future of global life health development.